Pathophysiology and management of meningococcal septicaemia

Journal of the Royal College of Physicians of London

Volumn 34, Issue 5, 2000, Pages 436-444

  Pathan, Nazima ^b   Nadel, Simon ^b   Levin, Michael ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIINFLAMMATORY AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; LIPOPOLYSACCHARIDE; PROTEIN C; STREPTOKINASE; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; EPITHELIUM CELL; EXTRACORPOREAL OXYGENATION; HEMOFILTRATION; HOST RESISTANCE; HUMAN; IMMUNOPATHOLOGY; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; SEPTICEMIA; SEROTYPE;

ALGORITHMS; CHILD; CRITICAL CARE; HUMAN; MENINGOCOCCAL INFECTIONS; SUPPORT, NON-U.S. GOV'T;

EID: 0033783626     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Platt MJ. Child health statistical review, 1997. Arch Dis Child 1997;77:542-8.
2. Invasive meningococcal infections. Commun Dis Rep CDR Wkly 1995;5:5.
3. Riordan FA, Marzouk O, Thomson AP, Sills JA, Hart CA. The changing presentations of meningococcal disease. Eur J Pediatr 1995;154:472-4.
4. Ramsay M, Kaczmarski E, Rush M, Mallard R, et al. Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales. Commun Dis Rep CDR Rev 1997;7:R49-54.
5. Lapeyssonnie L. La méningite cérébrospinale en Afrique. Bull WHO 1963; 28(Suppl 1)3-114.
6. Moore PS, Hierholzer J, DeWitt W, Gouan K, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 1990;264:1271-5.
7. Virji M, Kayhty H, Ferguson DJ, Alexandrescu C, et al. The role of pili in the interactions of pathogenic Neisseria with cultured human endothelial cells. Mol Microbiol 1991;5:1831-41.
8. Stephens DS, McGee ZA, Melly MA, Hoffman LH, Cregg CR. Attachment of pathogenic Neisseria to human mucosal surfaces: role in pathogenesis. Infection 1982;10:192-5.
9. de Vries FP, Cole R, Dankert J, Frosch M, van Putten JP. Neisseria meningitidis producing the Ope adhesin binds epithelial cell proteoglycan receptors. Mol Microbiol 1998;27:1203-12.
10. Vitovski S, Read RC, Sayers JR. Invasive isolates of Neisseria meningitidis possess enhanced immunoglobulin A1 protease activity compared to colonizing strains. FASEB J 1999;13:331-7.
11. Nassif X, So M. Interaction of pathogenic neisseriae with nonphagocytic cells. Clin Microbiol Rev 1995;8:376-88.
12. de Vries FP, Van Der Ende A, van Putten JP, Dankert J. Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens. Infect Immun 1996;64:2998-3006.
13. Mulks MH, Plaut AG. IgA protease production as a characteristic distinguishing pathogenic from harmless neisseriaceae. N Engl J Med 1978;299:973-6.
14. Virji M, Makepeace K, Peak IR, Ferguson DJ, et al. Ope-and pilus-dependent interactions of meningococci with human endothelial cells: molecular mechanisms and modulation by surface polysaccharides. Mol Microbiol 1995;18:741-54.
15. Vogel U, Hammerschmidt S, Frosch M. Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are prerequisites for virulence of meningococci in the infant rat. Med Microbiol Immunol (Berl) 1996;185:81-7.
16. Klein NJ, Ison CA, Peakman M, Levin M, et al. The influence of capsulation and lipooligosaccharide structure on neutrophil adhesion molecule expression and endothelial injury by Nesseria meningitidis. J Infect Dis 1996:173:172-9.
17. Estabrook MM, Griffiss JM, Jarvis GA. Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect Immun 1997; 65:4436-44.
18. Jarvis GA, Vedros NA. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun 1987;55:174-80.
19. Andersen BM. Endotoxin release from Neisseria meningitidis. Relationship between key bacterial characteristics and meningococcal disease. Review. Scand J Infect Dis 1989;64(Suppl):1-43.
20. Peter G, Weigert MB, Bissel AR, Gold R, et al. Meningococcal meningitis in familial deficiency of the fifth component of complement. Pediatrics 1981;67:882-6.
21. Herva E, Leinonen M, Kayhty H, Makela PH, Vetoniemi-Korhonen SL. Recurrent meningococcal meningitis due to partial complement defects and poor anti-meningococcal antibody response. J Infect 1983;6:55-60.
22. Sjoholm AC, Braconier JH, Soderstrom C Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 1982;50:291-7.
23. Ross SC, Densen P. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 1984;63:243-73.
24. Ernst T, Spath PJ, Aebi C, Schaad UB, Bianchetti MG. Screening for complement deficiency in bacterial meningitis. Acta Paediatr 1997;86:1009-10.
25. Jack DL, Dodds AW, Anwar N, Ison CA, et al. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B. J Immunol 1998;160: 1346-53.
26. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 1999;353:1049-53.
27. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996;174:878-80.
28. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;i:355-7.
29. Gardlund B, Sjolin J, Nilsson A, Roll M, et al. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995; 172:296-301.
30. Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989;159:195-204.
31. Brandtzaeg P, Joo GB, Brusletto B, Kierulf P. Plasminogen activator inhibitor 1 and 2, alpna-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 1990;57:271-8.
32. Kornelisse RF, Hazelzet JA, Savelkoul HF, Hop WC, et al. The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis 1996;173:1148-56.
33. Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999;354:561-3.
34. Flaegstad T, Kaaresen PI, Stokland T, Cutteberg T. Factors associated with fatal outcome in childhood meningococcal disease. Acta Paediatr 1995;84:1137-42.
35. LeClerc F, Beuscart R, Guillois B, Diependaele JF, et al. Prognostic factors of severe infectious purpura in children. Intensive Care Med 1985;11:140-3.
36. Mercier JC, Beaufils F, Hartmann JF, Azema D. Hemodynamic patterns of meningococcal shock in children. Crit Care Med 1988;16:27-33.
37. Fijnvandraat K, Peters M, Derkx B, Van Deventer S, ten Cate JW. Endotoxin induced coagulation activation and protein C reduction in meningococcal septic shock. Prog Clin Biol Res 1994;388:247-54.
38. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995;73:15-20.
39. Brandtzaeg P, Sandset PM, Joo GB, Ovstebo R, et al. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 1989;55:459-70.
40. Heyderman RS, Klein NJ, Daramola OA, Hammerschmidt S, et al. Induction of human endothelial tissue factor expression by Neisseria meningitidis: the influence of bacterial killing and adherence to the endothelium. Microb Pathog 1997;22:265-74.
41. Monsalve F, Rucabadol L, Salvador A, Bonastre J, et al. Myocardial depression in septic shock caused by meningococcal infection. Crit Care Med 1984;12:1021-3.
42. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation 1986;73:637-44.
43. Dhainaut JF, Huyghebaert MF, Monsallier JF, Lefevre G, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987;75:533-41.
44. Parrillo JE, Burch C, Shelhamer JH, Parker MM, et al. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 1985;76: 1539-53.
45. Hazelzet JA, van der Voort E, Lindemans J, ter Heerdt PJ, Neijens HJ. Relation between cytokines and routine laboratory data in children with septic shock and purpura. Intensive Care Med 1994;20:371-4.
46. van Deuren M, van der Ven-Jongekrijg J, Bartelink AK, van Dalen R, et al. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 1995;172:433-9.
47. Visser JJ, Scholten RJ, Hoekman K. Nitric oxide synthesis in meningococcal meningitis. Ann Intern Med 1994;120:345-6.
48. Khilnani P. Electrolyte abnormalities in critically ill children. Crit Care Med 1992;20:241-50.
49. Chernow B. Calcium: does it have a therapeutic role in sepsis? Crit Care Med 1990;18:895-6.
50. Gauthier B, Trachtman H, Di Carmine F, Urivetsky M, et al. Hypocalcemia and hypercalcitoninemia in critically ill children. Crit Care Med 1990;18:1215-9.
51. Mauger DC. Hypokalaemia as a consistent feature of fulminant meningococcal septicaemia. Aust Paediatr J 1971;7:84-6.
52. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet 1998;352: 391-6.
53. Pollard AJ, Britto J, Nadel S, de Munter C, et al. Emergency management of meningococcal disease. Arch Dis Child 1999;80:290-6.
54. Neu HC. Cephalosporins in the treatment of meningitis. Drugs 1987;34(Suppl 2):135-53.
55. Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA 1991;266:1242-5.
56. Dula DJ, Lutz P, Vogel MF, Weaver BN. Rapid flow rates for the resuscitation of hypovolemic shock. Ann Emerg Med 1985;14:303-6.
57. Nadel S, De Munter C, Britto J, Levin M, Habibi P. Albumin: saint or sinner? Arch Dis Child 1998;79:384-5.
58. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. Br Med J 1998;317:235-40.
59. Tobin JR, Wetzel RC Shock and multiorgan failure. In: Rogers MC (ed). Textbook of pediatric intensive care. Baltimore: Williams and Wilkins, 1996:555-605.
60. Haneberg B, Gutterberg TJ, Moe PJ, Osterud B, et al. Heparin for infants and children with meningococcal septicemia. Results of a randomized therapeutic trial. NIPH Ann 1983;6:43-7.
61. Zenz W, Muntean W, Zobel G, Grubbauer HM, Gallistl S. Treatment of fulminant meningococcemia with recombinant tissue plasminogen activator. Thromb Haemost 1995;74:802-3.
62. Keeley SR, Matthews NT, Buist M. Tissue plasminogen activator for gangrene in fulminant meningococcaemia. Lancet 1991;337:1359.
63. Smith OP, White B, Vaughan D, Rafferty M, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997;350:1590-3.
64. Kreuz W, Veldman A, Escuriola-Ettingshausen C, Schneider W, Beeg T. Protein-C concentrate for meningococcal purpura fulminans [letter; comment]. Lancet 1998;351:986-7.
65. Finn A, Booy R, Levin M, Nadel S, Faust S. Infectious purpura fulminans: caution needed in the use of protein C. Br J Haematol 1999;106:253-4.
66. Cohen J. Monoclonal antibody to TNF alpha in septic shock [letter]. Lancet 1998;351:1731.
67. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994;121: 1-5.
68. Giroir BP, Quint PA, Barton P, Kirsch EA, et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 1997;350:1439-43.
69. Lepow ML, Beeler J, Randolph M, Samuelson JS, Hankins WA. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J Infect Dis 1986;154:1033-6.
70. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;ii:355-7.
71. de Moraes JC, Perkins BA, Camargo MC, Hidalgo NT, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340: 1074-8.
72. Costa EA. Effectiveness of meningococcal vaccine in Brazil. Int J Epidemiol 1997; 26:681-4.